A new recombinant factor VIII: from genetics to clinical use by Santagostino E

Get full text

GlycoPEGylated recombinant factor IX for hemophilia B in context by Santagostino E, Mancuso ME

Get full text

Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia by Riva S, Nobili A, Djade CD, Mancuso ME, Santagostino E, Pravettoni G

Get full text

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A by Di Minno G, Santagostino E, Morfini M, Ettorre C, Cultrera D, Baldacci E, Russo E, Gallucci C

Get full text

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials by Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD

Get full text

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? by Rodriguez-Merchan, E, Hedner, U, Heijnen, L, Jimenez-Yuste, V, Lee, C, Morfini, M, Querol, F, Roosendaal, G, Santagostino, E, Solimeno, L

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). by Curry, N, Albayrak, C, Escobar, M, Andre Holme, P, Kearney, S, Klamroth, R, Misgav, M, Négrier, C, Wheeler, A, Santagostino, E, Shima, M, Landorph, A, Tønder, SM, Lentz, SR